JP2021523120A5 - - Google Patents

Info

Publication number
JP2021523120A5
JP2021523120A5 JP2020561740A JP2020561740A JP2021523120A5 JP 2021523120 A5 JP2021523120 A5 JP 2021523120A5 JP 2020561740 A JP2020561740 A JP 2020561740A JP 2020561740 A JP2020561740 A JP 2020561740A JP 2021523120 A5 JP2021523120 A5 JP 2021523120A5
Authority
JP
Japan
Prior art keywords
peaks
acid
compound
salt according
furthermore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523120A (ja
JP7324778B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030717 external-priority patent/WO2019213606A2/en
Publication of JP2021523120A publication Critical patent/JP2021523120A/ja
Publication of JP2021523120A5 publication Critical patent/JP2021523120A5/ja
Application granted granted Critical
Publication of JP7324778B2 publication Critical patent/JP7324778B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561740A 2018-05-04 2019-05-03 セルデュラチニブ(cerdulatinib)の固体形態 Active JP7324778B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667226P 2018-05-04 2018-05-04
US62/667,226 2018-05-04
PCT/US2019/030717 WO2019213606A2 (en) 2018-05-04 2019-05-03 Solid forms of cerdulatinib

Publications (3)

Publication Number Publication Date
JP2021523120A JP2021523120A (ja) 2021-09-02
JP2021523120A5 true JP2021523120A5 (cg-RX-API-DMAC7.html) 2022-05-12
JP7324778B2 JP7324778B2 (ja) 2023-08-10

Family

ID=66641481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561740A Active JP7324778B2 (ja) 2018-05-04 2019-05-03 セルデュラチニブ(cerdulatinib)の固体形態

Country Status (5)

Country Link
US (2) US10865198B2 (cg-RX-API-DMAC7.html)
EP (1) EP3788035B1 (cg-RX-API-DMAC7.html)
JP (1) JP7324778B2 (cg-RX-API-DMAC7.html)
TW (1) TW202014412A (cg-RX-API-DMAC7.html)
WO (1) WO2019213606A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3383396B1 (en) 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2019213606A2 (en) * 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CA2723205C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
ES2546294T7 (es) 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
US20110130415A1 (en) 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
US9398308B2 (en) 2010-07-28 2016-07-19 Qualcomm Incorporated Coding motion prediction direction in video coding
WO2012045020A1 (en) * 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016196385A1 (en) 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
EP3383396B1 (en) 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2019213606A2 (en) * 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
KR20210003789A (ko) 2018-05-04 2021-01-12 포톨라 파마슈티컬스, 인코포레이티드 림프종을 치료하는 방법

Similar Documents

Publication Publication Date Title
JP7036939B2 (ja) 癌細胞の成長抑制効果を示す新規なピリミジン誘導体及びそれを含む薬剤学的組成物
JP7126514B2 (ja) アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス
CN103930399B (zh) 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物
TW438781B (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
TWI425945B (zh) 四氫異喹啉-1-酮衍生物或其鹽
US20080293711A1 (en) Chemokine receptor modulators
JP4937760B2 (ja) 4−(4−メチルピペラジン−1−イルメチル)−n−[4−メチル−3−(4−ピリジン−3−イル)ピリミジン−2−イルアミノ)フェニル]−ベンズアミドの塩形態
TW201000460A (en) Amide compound
JP4429724B2 (ja) [1,2,4]−トリアゾール二環式アデノシンA2aレセプタアンタゴニスト
TW200307539A (en) Cycloalkyl inhibitors of potassium channel function
WO2008109154A1 (en) Chemokine receptor modulators
TW200932727A (en) New acetyl coenzyme a carboxylase (ACC) inhibitors and uses in treatments of obesity and diabetes mellitus
TW200913997A (en) Heterocyclic compounds
CZ20033508A3 (en) 5-ht receptor ligands and uses thereof
CN101258131B (zh) 作为5-HT2c受体激动剂的6-芳烷基氨基-2,3,4,5-四氢-1H-苯并[d]氮杂䓬
JP2009514782A (ja) グリコーゲン合成酵素キナーゼ3阻害剤としてのトリアゾロピリミジン誘導体
EP3822263A1 (en) Biaryl ether-type quinazoline derivative
TW200815368A (en) 2-anilino-4-aminoalkyleneaminopyrimidines
EP3107898A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
CN102741226B (zh) 4-取代的-2-苯氧基-苯胺δ阿片类受体调节剂
JP2010505961A5 (cg-RX-API-DMAC7.html)
EP2906554A1 (en) Solid forms of nilotinib hydrochloride
JP2023078389A (ja) 重水素化デファクチニブ化合物及びその使用
HK1232226A1 (zh) 抑制bet蛋白的具有间位取代的芳族氨基或醚基的3,4-二氢吡啶并[2,3-b]吡嗪酮
JP6976248B2 (ja) (r)−1−(4−(6−(2−(4−(3,3−ジフルオロシクロブトキシ)−6−メチルピリジン−2−イル)アセトアミド)ピリダジン−3−イル)−2−フルオロブチル)−n−メチル−1h−1,2,3−トリアゾール−4−カルボキサミドの塩形態および多形体